212 related articles for article (PubMed ID: 10498834)
1. Recovery of dopamine neuronal transporter but lack of change of its mRNA in substantia nigra after inactivation by a new irreversible inhibitor characterized in vitro and ex vivo in the rat.
Régo JC; Syringas M; Leblond B; Costentin J; Bonnet JJ
Br J Pharmacol; 1999 Sep; 128(1):51-60. PubMed ID: 10498834
[TBL] [Abstract][Full Text] [Related]
2. Dopamine transporter activity in the substantia nigra and striatum assessed by high-speed chronoamperometric recordings in brain slices.
Hoffman AF; Lupica CR; Gerhardt GA
J Pharmacol Exp Ther; 1998 Nov; 287(2):487-96. PubMed ID: 9808671
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and transporter binding properties of bridged piperazine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909).
Zhang Y; Rothman RB; Dersch CM; de Costa BR; Jacobson AE; Rice KC
J Med Chem; 2000 Dec; 43(25):4840-9. PubMed ID: 11123994
[TBL] [Abstract][Full Text] [Related]
4. Unilateral infusion of a dopamine transporter antisense into the substantia nigra protects against MDMA-induced serotonergic deficits in the ipsilateral striatum.
Kanthasamy A; Sprague JE; Shotwell JR; Nichols DE
Neuroscience; 2002; 114(4):917-24. PubMed ID: 12379247
[TBL] [Abstract][Full Text] [Related]
5. Serotonin uptake into dopamine neurons via dopamine transporters: a compensatory alternative.
Zhou FC; Lesch KP; Murphy DL
Brain Res; 2002 Jun; 942(1-2):109-19. PubMed ID: 12031859
[TBL] [Abstract][Full Text] [Related]
6. Studies of the biogenic amine transporters. VIII: identification of a novel partial inhibitor of dopamine uptake and dopamine transporter binding.
Rothman RB; Dersch CM; Carroll FI; Ananthan S
Synapse; 2002 Mar; 43(4):268-74. PubMed ID: 11835522
[TBL] [Abstract][Full Text] [Related]
7. Evidence for the sequential formation of two complexes between an uptake inhibitor, GBR 12783 [1-[2-(diphenylmethoxy)ethyl]-4-(3-phenyl-2-propenyl)piperazine], and the neuronal transporter of dopamine.
Do-Régo JC; Hue H; Costentin J; Bonnet JJ
J Neurochem; 1999 Jan; 72(1):396-404. PubMed ID: 9886093
[TBL] [Abstract][Full Text] [Related]
8. Evidence that pure uptake inhibitors including cocaine interact slowly with the dopamine neuronal carrier.
Héron C; Costentin J; Bonnet JJ
Eur J Pharmacol; 1994 Nov; 264(3):391-8. PubMed ID: 7698180
[TBL] [Abstract][Full Text] [Related]
9. [3H]substrate- and cell-specific effects of uptake inhibitors on human dopamine and serotonin transporter-mediated efflux.
Johnson RA; Eshleman AJ; Meyers T; Neve KA; Janowsky A
Synapse; 1998 Sep; 30(1):97-106. PubMed ID: 9704886
[TBL] [Abstract][Full Text] [Related]
10. Specific binding of [3H]GBR 12783 to the dopamine neuronal carrier included in polarized membranes.
Billaud G; Costentin J; Bonnet JJ
Eur J Pharmacol; 1993 Nov; 247(3):333-40. PubMed ID: 8307105
[TBL] [Abstract][Full Text] [Related]
11. Translocation of dopamine and binding of 2 beta-carbomethoxy-3 beta-(4-fluorophenyl) tropane (WIN 35,428) measured under identical conditions in rat striatal synaptosomal preparations. Inhibition by various blockers.
Xu C; Coffey LL; Reith ME
Biochem Pharmacol; 1995 Jan; 49(3):339-50. PubMed ID: 7857321
[TBL] [Abstract][Full Text] [Related]
12. Decreased densities of dopamine and serotonin transporters and of vesicular monoamine transporter 2 in severely kainic acid lesioned subregions of the striatum.
Naudon L; Leroux-Nicollet I; Boulay D; Costentin J
J Neural Transm (Vienna); 2001; 108(4):431-44. PubMed ID: 11475010
[TBL] [Abstract][Full Text] [Related]
13. Tolerance in the replacement of the benzhydrylic O atom in 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives by an N atom: development of new-generation potent and selective N-analogue molecules for the dopamine transporter.
Dutta AK; Xu C; Reith ME
J Med Chem; 1998 Aug; 41(17):3293-7. PubMed ID: 9703474
[TBL] [Abstract][Full Text] [Related]
14. Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model.
Sandoval V; Riddle EL; Ugarte YV; Hanson GR; Fleckenstein AE
J Neurosci; 2001 Feb; 21(4):1413-9. PubMed ID: 11160413
[TBL] [Abstract][Full Text] [Related]
15. In vivo electrochemical studies of dopamine clearance in the rat substantia nigra: effects of locally applied uptake inhibitors and unilateral 6-hydroxydopamine lesions.
Hoffman AF; Gerhardt GA
J Neurochem; 1998 Jan; 70(1):179-89. PubMed ID: 9422361
[TBL] [Abstract][Full Text] [Related]
16. Differential sensitivity to NaCl for inhibitors and substrates that recognize mutually exclusive binding sites on the neuronal transporter of dopamine in rat striatal membranes.
Tidjane Corera A; Do-Régo JC; Costentin J; Bonnet JJ
Neurosci Res; 2001 Mar; 39(3):319-25. PubMed ID: 11248372
[TBL] [Abstract][Full Text] [Related]
17. Destruction of midbrain dopaminergic neurons by using immunotoxin to dopamine transporter.
Wiley RG; Harrison MB; Levey AI; Lappi DA
Cell Mol Neurobiol; 2003 Oct; 23(4-5):839-50. PubMed ID: 14514035
[TBL] [Abstract][Full Text] [Related]
18. Novel in vivo electrophysiological assay for the effects of cocaine and putative "cocaine antagonists" on dopamine transporter activity of substantia nigra and ventral tegmental area dopamine neurons.
Hinerth MA; Collins HA; Baniecki M; Hanson RN; Waszczak BL
Synapse; 2000 Dec; 38(3):305-12. PubMed ID: 11020233
[TBL] [Abstract][Full Text] [Related]
19. Food deprivation decreases mRNA and activity of the rat dopamine transporter.
Patterson TA; Brot MD; Zavosh A; Schenk JO; Szot P; Figlewicz DP
Neuroendocrinology; 1998 Jul; 68(1):11-20. PubMed ID: 9695934
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological properties of new 2beta-alkyl- and 2beta-aryl-3-(substituted phenyl)tropane derivatives: stereochemical effect of C-3 on affinity and selectivity for neuronal dopamine and serotonin transporters.
Kozikowski AP; Araldi GL; Prakash KR; Zhang M; Johnson KM
J Med Chem; 1998 Dec; 41(25):4973-82. PubMed ID: 9836615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
